Obviously, these look great. But I still like GILD's triplet because it's simpler - don't need to figure out if a patient is cirrhotic or not and can treat anyone regardless of their previous experience (just need to go to 12 weeks instead of 8 if they are DAA-experienced). Not to mention the single pill advantage. Simplicity is what the next wave of regimens is supposed to be all about.
Market Data 
Markets 
AI
